Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RepliCel Life Sciences Inc. (REPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1908-0.0151 (-7.34%)
At close: 10:01AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2059
Open0.1908
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1908 - 0.1908
52 Week Range0.1700 - 0.4660
Volume2,000
Avg. Volume6,272
Market Cap7.858M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for REPCF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • REPLICEL LIFE SCIENCES INC
    Analyst Report: Procter & Gamble Co.Procter & Gamble, with headquarters in Cincinnati, and sales in over 180 countries, manufactures daily-use household, personal care, food and paper products. Fiscal 2021 sales were $76.1 billion. The company's major brands include Tide, Gillette, Pampers, Bounty, Crest, Ivory, Head & Shoulders, Scope, Oral-B, Swiffer, Tampax and Charmin. Approximately 47% of sales are from North America, 22% from Europe, 10% from Asia Pacific, 9% from Greater China, 6% from Latin America, and 6% from India, Middle East & Africa. By product category, there are five business segments: Fabric & Home Care (34% of sales); Baby, Feminine & Family Care (25%); Beauty (19%); Grooming (9%); and Health Care (13%). Ivory Soap was one of the company's first and most innovative products. The 'Soap that floats,' was a helpful innovation more than 130 years ago when many Americans still bathed in murky rivers and streams. The company's fiscal year ends on June 30. The quarters are: 1Q (July, August, September); 2Q (October, November, December); 3Q (January, February, March); 4Q (April, May, June).
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • ACCESSWIRE

    RepliCel Announces Material Patent Milestones

    New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce the filing of a new patent application covering novel aspects of the De

  • ACCESSWIRE

    RepliCel Closed Final Tranche of Strategic Investment Commitment

    VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has closed the final tranche of the investment by MainPointe Pharmaceuticals ("MainPointe") as outlined in the share purchase agreement signed by the parties earlier this year.

  • ACCESSWIRE

    RepliCel Terminates License Agreement with Shiseido

    VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido.

Advertisement
Advertisement